Drugs / NISOTIROSTIDE
NISOTIROSTIDE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05582096 | Nov 2022 → Jun 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05377333 | Jun 2022 → Nov 2023 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04641312 | Nov 2020 → Dec 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06897475 | Mar 2025 → May 2027 expected | type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NISOTIROSTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315028 ↗ |
| Known as | LY3457263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04641312 ↗ |
| Known as | Nisostirotide | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315028 ↗ |
| Known as | Nisotirostida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315028 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5315028 ↗ |
| Route | Subcutaneous | “Administered SC” NCT04641312 ↗ |